Ubix & Yuhan have signed an exclusive license agreement for the development & commercialization of UBX-103 to treat mCRPC
As per the agreement, Yuhan gains UBX-103’s exclusive global rights to carry out preclinical & clinical studies plus commercialization. Ubix is entitled to receive $3.6M upfront, ~$105M development, regulatory & commercial milestones along with high single-digit royalty. It will receive profit sharing on sublicensing to a 3rd party
Additionally, UBX-103 showed AR degradation with picomolar DC50, effectiveness against treatment-induced resistance mutations and tumor growth inhibition that are resistant to next-gen. hormonal therapy in the in vivo preclinical model
Ref: Ubix Therapeutics | Image: Ubix Therapeutics
Related News:- Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
